Finoriq research workspace
Advanced Biomed Inc. (ADVB) Historical Metrics
Advanced Biomed Inc., an investment holding company, engages in the research and development of. Review ADVB valuation ratios, fundamentals, and filing metrics on Finoriq.
Company Snapshot
Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment in Taiwan. Its devices include A+Pre, an automated sample preparation system that enables pre-concentration of diluted blood samples; AC-1000, a rare cell device to solve the problem of detection of hypercoagulable state samples of tumor patients; A+SCDrop, a circulating tumor cell (CTC) single-cell capture device; and A+CellScan, an analyzer with an immunostaining chip for immunostaining/analysis of the AC-1000 product. The company also offers microfluidic biochips, such as A+Pre, AC-1000 CTC enrichment, and A+CellScan chips to provide assay products and services to cancer patients. In addition, its immunochromogenic kits include A+CTCE kit to identify epithelial circulating tumor cells and determined by the immunochromogenicity of EpCAM, CK (pan), CD45, and CD14 antibodies; A+CTCM kit to identify mesenchymal circulating tumor cells based on the immunochromogenicity of Vimentin, CD45, and CD14 antibodies; A+EMT to identify epithelial-to-mesenchymal circulating tumor cells determined by the immunochromogenicity of cell-surface Vimentin, and CD45 and CD14 antibodies; and A+CM to identify tumor-associated macrophages based on the immunochromogenicity of PD-L1, CD45, and CD14 antibodies. Further, the company is developing A+LCGuard for early screening of lung cancer. Additionally, it establishes and operates medical clinics in the People's Republic of China. The company was founded in 2014 and is headquartered in New York, New York.
- Company
- Advanced Biomed Inc. (ADVB)
- Ticker
- ADVB
- Market Cap
- $14.7M
- Latest Price
- $8.8999
- Industry
- Medical Devices
Advanced Biomed Inc. (ADVB) Current Valuation Metrics
Static valuation preview for Advanced Biomed Inc. (ADVB). Market data retrieved 2026-07-09. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| P/EMarket cap divided by latest TTM net income. | 2.01x | Net Income | TTM Q2 2026 |
| Earnings YieldLatest TTM net income divided by market cap. | 49.8% | Net Income | TTM Q2 2026 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -69.1% | Operating Cash Flow | TTM Q2 2026 |
| Price / BookMarket cap divided by stockholders' equity. | 0.93x | Stockholders' Equity | Q2 2026 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.